Nuclear Medicine Market Analysis 2026

• Technological advancement in radiopharmaceuticals:

Radiopharmaceuticals are pharmaceutical preparations that include radioactive isotopes and are used for medicinal and diagnostic purposes. They are simple & small compounds That include a radioactive material used to treat cancer, heart, and neurological diseases. For cancer treatment, traditional chemotherapy techniques are replaced by more practical therapeutic radiopharmaceuticals, creating new opportunities in the radiopharmaceutical market. Additionally, compared to X-Rays and other external radiation imaging systems, it serves as a practical and safe option for patients as well as aiding doctors during diagnosis. Applications for radiopharmaceuticals, commonly referred to as nuclear medications, include lymphoma and bone metastases. 1-131, Ir-192, Y-90, 1-125, Lu-177, and Ra- 223 are employed in therapeutic operations, they are also used in diagnostic techniques. The increasing popularity of minimally invasive surgery compared to chemotherapy, the rise in cardiac patients, and the adoption of clear imaging techniques with the aid of diagnostic tools like PET & SPECT are major factors that propel the nuclear medicine market.

• Rising prevalence of chronic conditions:

The increasing incidence of chronic diseases such as cancer, respiratory disorders, neurological disorders, cardiovascular diseases, and metabolic disorders across the globe. According to Lymphoma Research Foundation over 1,00,000 people are diagnosed with lymphoma every year in the U.S. According to WHO cardiovascular diseases (CVDs) are the leading cause of death across the globe, taking an estimated 17.9 million lives each year. This leads to boosting nuclear medicines for both therapeutics and diagnostic purposes. The growing prevalence of these diseases is projected to drive the growth of the market during the forecast period.

Restraining Factor:

• The short half-life of radionuclides:

The radionuclides that are used in nuclear medicine procedures have short half-lives. For example, technetium-99m, one of the most commonly used medical isotopes for imaging studies has a half-life of 6 hours. Radiation and chemical degradation reduces radiochemical purity to an undesirable level, which can be fatal during diagnosis and treatment. Additionally, because radiopharmaceuticals have a shorter half-life, hospitals must produce their own radiopharmaceuticals on-site in cyclotrons or generators, which drives up the cost of capital for hospitals.

Impact of the COVID-19 Pandemic on the Nuclear Medicine Market:
COVID-19 coronavirus disease affected billions of people across the globe and severely disrupted life, leaving long-lasting social and economic despair, increasing strain on healthcare systems, shortage of medications, and radiotracers. This led to social distancing across the country, sanitization, and the use of personal protective equipment (PPE). At the beginning of April 2020, the healthcare system started to face the issues. In countries like the United States increase in death caused by ischemic heart disease and hypertensive heart disease. This may have been a consequence of additional stress from the pandemic and, marked disruption in cardiovascular diagnostic services including myocardial perfusion imaging. The usual clinical practice of nuclear medicine departments underwent a significant transformation despite the fact that they were not acknowledged as the front line of the pandemic response. Due to the mandated border lockdowns and consequent grounding of non-essential cargo aircraft, the pandemic reduced supply chains and interrupted distribution networks. The supply of essential tracers like 99mTc/99Mo and 131I, which are required radiopharmaceuticals for the bulk of conventional nuclear medicine research, was disrupted for nuclear medicine specifically as a result of these limitations and lockdowns. In fact, fewer radiotracers like molybdenum-99 were sent from Europe to the United States.

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Global Nuclear Medicine Market is witnessing significant growth in the near future.

In 2023, the Diagnostic segment accounted for noticeable share of global Nuclear Medicine Market and is projected to experience significant growth in the near future.

The Oncology segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies Eckert & Ziegler , Mallinckrodt and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

Frequently Asked Questions